Drug Discovery · Oncology Therapeutics
Viking Therapeutics revenue, results and funding
Viking Therapeutics holds $0 in public grants on record.
Data updated Nov 22, 2026 · Back to the company report
Results by year
| Year | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH |
|---|---|---|---|---|---|---|
| 2025 | $1k | – | $40.8M | $345M | −$393.3M | $165.8M |
| 2024 | $1k | – | $29.7M | $101.6M | −$150.9M | $26.7M |
| 2023 | $1k | – | $16.8M | $63.8M | −$100.8M | $55.5M |
| 2022 | $1k | $6.8M | $8.7M | $54.2M | −$70.4M | $36.6M |
| 2021 | $2k | – | $6.1M | $45M | −$55.7M | $26.4M |
| 2020 | $0 | – | $5.8M | $31.9M | −$42.7M | $29.1M |
| 2019 | $0 | – | $3.7M | $23.6M | −$32.7M | $8.4M |
| 2018 | $0 | – | $2.6M | $19M | −$26.2M | $24.8M |
| 2017 | $0 | – | $1.5M | $13.7M | −$19.1M | $9M |
| 2016 | $0 | $229 | $1.8M | $9M | −$13.8M | $3.1M |
| 2015 | – | $38 | $2.6M | $7M | −$12M | $769k |
| 2014 | – | $2 | $6.3k | $22.2M | −$23.5M | $756k |
| 2013 | – | – | – | – | – | $180k |
Sources: SEC
How to cite
Viking Therapeutics, Financials. Alion, Nov 22, 2026. https://alion.io/company/vikingtherapeutics/financials
